Bempikibart (ADX-914): A Comprehensive Report on an Investigational Anti-IL-7Rα Monoclonal Antibody for Autoimmune Diseases

1. Introduction to Bempikibart (ADX-914)

Overview of the Drug

Bempikibart, also identified by its research code ADX-914 and formerly BMS-986265, is an investigational biologic therapeutic agent.[1] It is classified as a fully human IgG1 kappa monoclonal antibody.[1] The primary molecular target of bempikibart is the alpha subunit of the interleukin-7 receptor (IL-7Rα).[2] The Chemical Abstracts Service (CAS) Registry Number for bempikibart is 2622254-57-1.[7]

Development History and Developer

Bempikibart is currently under development by Q32 Bio Inc..[2] The development pathway of bempikibart has involved several entities. Q32 Bio regained full worldwide development and commercial rights to bempikibart from Amgen in November 2023.[11] Amgen had acquired these rights through its acquisition of Horizon Therapeutics.[11] Prior to Amgen's involvement, Horizon Therapeutics plc had entered into a collaboration and option agreement with Q32 Bio in August 2022 to co-develop bempikibart for autoimmune diseases. Under this agreement, Horizon was to fund Phase 2 trials, with Q32 Bio managing operational aspects.[11] The earliest developmental code name identified in the provided materials is BMS-986265, suggesting initial work may have been conducted by or in association with Bristol Myers Squibb before Q32 Bio took leadership of the program.[8] This sequence of acquisitions and collaborations—from Bristol Myers Squibb to Q32 Bio, then a partnership with Horizon, its subsequent acquisition by Amgen, and finally Q32 Bio's re-acquisition of full rights—illustrates a complex but not uncommon trajectory for pharmaceutical assets. Such transitions can influence development timelines and strategic priorities. Q32 Bio's ultimate consolidation of worldwide rights signifies a strong commitment to bempikibart's potential